« Return to News | CROs/Service Providers | Technology Solutions

Parexel Releases eClinical Platform for Late-Stage Clinical Trials

Tuesday, April 13, 2010 07:26 AM

Parexel, a CRO, released a new web-based platform to be used in late-phase clinical research to help users meet regulatory guidelines and ensure high quality data. The new product combines the expertise of Parexel’s existing Peri Approval Clinical Excellence (PACE) team with the eClinical capabilities of Perceptive Informatics, Parexel’s technology subsidiary. The platform allows for a variety of eClinical services, such as clinical trial management systems, electronic data capture, randomization and trial supply management, and electronic patient-reported outcomes, to be incorporated in late-phase studies.

"Post-approval studies have continued to expand measurably in number, size, and complexity in recent years. As a result, biopharmaceutical companies require much greater efficiency in managing the high volume throughput of data while controlling the costs related to these programs. We are focused on helping clients achieve greater efficiency by gathering more data at a significantly lower cost per patient," said Carol Collins, Ph.D., corporate vice president and worldwide head of PACE, in a statement.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.